Relationship between longitudinal behaviour of some markers of eye autoimmunity and changes in ocular findings in patients with graves' ophthalmopathy receiving corticosteroid therapy

Clinical Endocrinology

Volumn 59, Issue 3, 2003, Pages 388-395

  De Bellis, Annamaria ^a   Bizzarro, Antonio ^a   Conte, Marisa ^a   Coronella, Concetta ^a   Solimeno, Stefano ^a   Perrino, Silvia ^a   Sansone, Daniela ^a   Guaglione, Mariangela ^a   Wall, Jack R ^b   Bellastella, Antonio ^a  

^a SECOND UNIVERSITY OF NAPLES   (Italy)

^b GEELONG HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; BIOLOGICAL MARKER; CORTICOSTEROID; EXTRAOCULAR MUSCLE ANTIBODY; G2S ANTIBODY; METHYLPREDNISOLONE; MUSCLE ANTIBODY; THIAMAZOLE; THYROTROPIN RECEPTOR ANTIBODY; UNCLASSIFIED DRUG;

ADULT; ANTIBODY TITER; ARTICLE; AUTOIMMUNITY; CLINICAL EXAMINATION; CLINICAL FEATURE; CONTROLLED STUDY; CORRELATION ANALYSIS; CORTICOSTEROID THERAPY; COST BENEFIT ANALYSIS; DIPLOPIA; DISEASE ACTIVITY; DISEASE COURSE; DISEASE SEVERITY; DRUG MONITORING; ENDOCRINE OPHTHALMOPATHY; ENZYME LINKED IMMUNOSORBENT ASSAY; EUTHYROIDISM; EXOPHTHALMOS; EYE; FEMALE; FOLLOW UP; GENERAL CONDITION IMPROVEMENT; GRAVES DISEASE; HUMAN; HUMAN TISSUE; IMMUNOFLUORESCENCE; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; PREDICTION; PRIORITY JOURNAL; RADIOIMMUNOASSAY; SCORING SYSTEM; STATISTICAL SIGNIFICANCE; TREATMENT OUTCOME;

ADULT; ANTITHYROID AGENTS; AUTOANTIBODIES; BIOLOGICAL MARKERS; DIPLOPIA; EXOPHTHALMOS; EYE; EYE PROTEINS; FEMALE; FOLLOW-UP STUDIES; GLUCOCORTICOIDS; GRAVES DISEASE; HUMANS; INFUSIONS, INTRAVENOUS; MALE; MEMBRANE PROTEINS; METHIMAZOLE; METHYLPREDNISOLONE; MIDDLE AGED; RECEPTORS, THYROTROPIN; STATISTICS, NONPARAMETRIC;

EID: 0042326307     PISSN: 03000664     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2265.2003.01861.x     Document Type: Article

References (33)

1. Amato, G., Rotondi, M., Salzano, I., De Bellis, A., De Felice, G., Costagliola, C., Bellastella, A. & Carella, C. (2000) Extraocular muscle antibodies positivity as the only serum marker of euthyroid Graves' ophthalmopathy following subacute thyroiditis: case report. Journal of Clinical Endocrinology and Metabolism, 85, 950-952.
2. Bahn, R.S. & Heufelder, A.E. (1993) Pathogenesis of Graves' ophthalmopathy. New England Journal of Medicine, 329, 1468-1475.
3. Bartalena, L., Marcocci, C., Bogazzi, F., Bruno-Bossio, G. & Pinchera, A. (1991) Glucocorticoid therapy of Graves' ophthalmopathy. Experimental and Clinical Endocrinology, 97, 320-328.
4. Bartalena, L., Marcocci, C. & Pinchera, A. (1997) Treating severe Graves' ophthalmopathy. Bailliere's Clinical Endocrinology and Metabolism, 11, 521-536.
5. Bartalena, L., Marcocci, C., Bogazzi, F., Manetti, L., Tanda, M.L., Dell'Unto, E., Bruno-Bossio, G., Nardi, M., Bartolomei, M.P., Lepri, A., Rossi, G., Martino, E. & Pinchera, A. (1998) Relation between therapy for hyperthyroidism and the course of Graves' ophthalmopathy. New England Journal of Medicine, 338, 73-78.
6. Bartalena, L., Pinchera, A. & Marcocci, C. (2000a) Management of Graves' ophthalmopathy: reality and perspectives. Endocrine Reviews, 21, 168-199.
7. Bartalena, L., Manetti, L., Tanda, M.L., Dell'Unto, E., Mazzi, B., Rocchi, R., Barbesino, G., Pinchera, A. & Marcocci, C. (2000b) Soluble interleukin-1 receptor antagonist concentration in patients with Graves' ophthalmopathy is neither related to cigarette smoking nor predictive of subsequent response to glucocorticoids. Clinical Endocrinology, 52, 647-651.
8. Bednarczuk, T., Hiromatsu, Y., Inoue, Y., Yamamoto, K., Wall, J.R. & Nauman, J. (2002) T-cell-mediated immunity in thyroid-associated ophthalmopathy. Thyroid, 12, 209-215.
9. Burch, H.B. & Wartofsky, L. (1993) Graves' ophthalmopathy: current concepts regarding pathogenesis and management. Endocrine Reviews, 14, 747-793.
10. De Bellis, A., Bizzarro, A., Rossi, R., Amoresano Paglionico, V., Criscuolo, T., Lombardi, G. & Bellastella, A. (1993) Remission of subclinical adrenocortical failure in subjects with adrenal autoantibodies. Journal of Clinical Endocrinology and Metabolism, 76, 1002-1007.
11. De Bellis, A., Bizzarro, A., Amoresano Paglionico, V., Di Martino, S., Criscuolo, T., Sinisi, A.A., Lombardi, G. & Bellastella, A. (1994) Detection of vasopressin cell antibodies in some patients with autoimmune endocrine disease without overt diabetes insipidus. Clinical Endocrinology, 40, 173-177.
12. De Bellis, A., Di Martino, S., Fiordalisi, F., Muccitelli, V.I., Sinisi, A.A., Abbate, G.F., Gargano, D., Bellastella, A. & Bizzarro, A. (1998) Soluble intercellular adhesion molecule-1 (sICAM-1) concentrations in Graves' disease patients followed up for development of ophthalmopathy. Journal of Clinical Endocrinology and Metabolism, 83, 1222-1225.
13. De Bellis, A., Colao, A., Bizzarro, A., Di Salle, F., Coronella, C., Solimeno, S., Vetrano, A., Pivonello, R., Pisano, G., Lombardi, G. & Bellastella, A. (2002) Longitudinal study of vasopressin cell antibodies and of hypothalamic-pituitary region on magnetic resonance imaging in patients with autoimmune and idiopathic complete central diabetes insipidus. Journal of Clinical Endocrinology and Metabolism, 87, 3825-3829.
14. Feliciello, A., Porcellini, A., Ciullo, I., Bonavolontà, G., Avvedimento, E.V. & Fenzi, G. (1993) Expression of thyrotropin-receptor mRNA in healthy and Graves' disease retro-orbital tissue. Lancet, 342, 337-338.
15. Frewin, S., Dickinson, A.J., Kendall-Taylor, P. & Perros, P. (2000) Intravenous methylprednisolone pulse therapy for thyroid-associated ophthalmopathy: in-patient or day case treatment? Journal of Endocrinology, 164 (Suppl. 1), 362.
16. Gerding, M.N., van der Meer, J.W.C., Broenink, M., Bakker, O., Wiersinga, W.M. & Prummel, M.F. (2000) Association of thyrotrophin receptor antibodies with the clinical features of Graves' ophthalmopathy. Clinical Endocrinology, 52, 267-271.
17. Gunji, K., De Bellis, A., Kubota, S., Swanson, J., Wengrowicz, S., Cochran, B., Ackrell, B.A.C., Salvi, M., Bellastella, A., Bizzarro, A., Sinisi, A.A. & Wall, J.R. (1999) Serum antibodies against the flavoprotein subunit of succinate dehydrogenase are sensitive markers of eye muscle autoimmunity in patients with Graves' hyperthyroidism. Journal of Clinical Endocrinology and Metabolism, 84, 1255-1262.
18. Gunji, K., De Bellis, A., Li, A.W., Yamada, M., Kubota, S., Ackrell, B., Wengrowicz, S., Bellastella, A., Bizzarro, A., Sinisi, A. & Wall, J.R. (2000) Cloning and characterization of the novel thyroid and eye muscle shared protein G2s: autoantibodies against G2s are closely associated with ophthalmopathy in patients with Graves' hyperthyroidism. Journal of Clinical Endocrinology and Metabolism, 85, 1641-1647.
19. Heufelder, A.E. (1997) Retro-orbital autoimmunity. Bailliere's Clinical Endocrinology and Metabolism, 11, 499-520.
20. Heufelder, A.E., Dutton, C.M., Sarkar, G., Donovan, K.A. & Bahn, R.S. (1993) Detection of TSH receptor mRNA in cultured fibroblast from patients with Graves' ophthalmopathy and pretibial dermopathy. Thyroid, 3, 297-300.
21. Hiromatsu, Y., Kaku, H., Miyake, I., Muruyama, S. & Soejima, E. (2002) Role of cytokines in the pathogenesis of thyroid-associated ophthalmopathy. Thyroid, 12, 217-221.
22. Inoue, Y., Tsuboi, T., Kouzaki, A., Maeda, T. & Inoue, T. (2002) Ophthalmic surgery in dysthyroid ophthalmopathy. Thyroid, 12, 257-263.
23. Kaspar, M., Archibald, C., De Bellis, A., Wu Li, A., Yamada, M., Chang, C.H., Kahaly, G. & Wall, J.R. (2002) Eye muscle antibodies and subtype of thyroid associated ophthalmopathy. Thyroid, 12, 187-191.
24. Kendall-Taylor, P., Crombie, A.L. & Perros, P. (1992) High-dose intravenous methylprednisolone pulse therapy in severe thyroid associated ophthalmopathy. Thyroid, 2 (Suppl. 1), S34.
25. Kubota, S., Gunji, K., Ackrell, B.A.C., Cochran, B., Stolarski, C., Wengrowicz, S., Kennerdell, J.S., Hiromatsu, Y. & Wall, J.R. (1998) The 64-kDa eye muscle protein is the flavoprotein subunit of mitochondrial succinate dehydrogenase: the corresponding serum antibodies are good markers of an immune-mediated damage to the eye muscle in patients with Graves' hyperthyroidism. Journal of Clinical Endocrinology and Metabolism, 83, 443-447.
26. Ludgate, M., Crisp, M., Lane, C., Costagliola, S., Vassart, G., Weetman, A., Daunerie, C. & Many, M.C. (1998) The thyrotropin receptor in thyroid eye disease. Thyroid, 8, 411-413.
27. Marcocci, C., Bartalena, L., Tanda, M.L., Manetti, L., Dell'Unto, E., Rocchi, R., Barbesino, G., Mazzi, B., Bartolomei, M.P., Lepri, P., Cartei, F., Nardi, M. & Pinchera, A. (2001) Comparison of effectiveness and tolerability of intravenous or oral glucocorticoids associated with orbital radiotherapy in the management of severe Graves' ophthalmopathy: results of a prospective, single-blind, randomized study. Journal of Clinical Endocrinology and Metabolism, 86, 3562-3567.
28. Matejka, G., Verges, B., Vaillant, G., Petit, J.M., Brun-Pacaud, A., Ridoni, S. & Brun, J.M. (1998) Intravenous methylprednisolone pulse therapy in the treatment of Graves' ophthalmopathy. Hormone and Metabolic Research, 30, 93-98.
29. Perros, P. & Kendall-Taylor, P. (1992) Antibodies to orbital tissues in thyroid associated ophthalmopathy. Acta Endocrinologica, 126, 137-142.
30. Perros, P., Crombie, A.L. & Kendall-Taylor, P. (1995) Natural history of thyroid-associated ophthalmopathy. Clinical Endocrinology, 42, 45-50.
31. Perros, P. & Kendell-Taylor, P. (2002) Medical treatment for thyroid-associated ophthalmopathy. Thyroid, 12, 241-244.
32. Perros, S., Wiersinga, W., Glinoer, D., Kendall-Taylor, P., Koornneef, L., Marcocci, C., Schleusener, H., Romaldini, J., Niepominiscze, H., Nagataki, S., Izumi, M., Inoue, Y., Stockigt, J., Wall, J.R., Greenspan, F., Solomon, D., Garrity, J. & Gorman, C.A. (1992) Classification of eye changes of Graves' disease. Thyroid, 2, 235-236.
33. Smith, T.J. (2002) Orbital fibroblasts exhibit a novel pattern of responses to proinflammatory cytokines: potential basis for the pathogenesis of thyroid-associated ophthalmopathy. Thyroid, 12, 197-203.